Ring finger protein 38 induces the drug resistance of cisplatin in non-small cell lung cancer

Lung Cancer

Cell Biol Int. 2020 Jul 24. doi: 10.1002/cbin.11423. Online ahead of print.


Cisplatin resistance of non-small cell lung cancer (NSCLC) needs to be well elucidated. RING finger protein (RNF38) has been proposed to as a biomarker of NSCLC poor prognosis. However, its role in drug resistance in NSCLC is poorly understood. RNF38 expression was detected in normal lung epithelial cell and four NSCLC cell lines. RNF38 was stably overexpressed in A549 and H460 cells or silenced in H1975 and cisplatin-resistant A549 cells (A549-CDDP resistant) using lentiviral vectors. RNF38

expression levels were determined using qRT-PCR and Western blot analysis. Cell viability in response to different concentrations of cisplatin was evaluated by CCK8 assay. RNF38 expression levels were markedly elevated in NSCLC cells and cells harboring high RNF38 were less sensitive to cisplatin. Overexpression of RNF38 reduced, while RNF38 silencing increased the drug sensitivity of cisplatin in NSCLC cells. Cisplatin-resistant cells expressed high RNF38 level. RNF38 silencing promoted cell apoptosis and enhanced the drug sensitivity of cisplatin in cisplatin-resistant NSCLC cells. These findings indicate that RNF38 might induce cisplatin resistance of NSCLC cells via promoting cell apoptosis and RNF38 could be a novel target for rectify cisplatin resistance in NSCLC cases. This article is protected by copyright. All rights reserved.